罗哌卡因联合酮咯酸切口浸润用于剖宫产术后镇痛:随机对照试验
该随机双盲试验评估在包含鞘内吗啡的多模式镇痛方案下,剖宫产术后使用罗哌卡因0.2%联合酮咯酸切口浸润泵注48小时的镇痛效果。主要结局为术后24小时活动痛评分,结果显示两组差异无统计学意义(中位数差0,95%CI -1~2,P=.94)。结论:在此类患者中,该切口浸润方案无额外获益。
要点
- 在鞘内吗啡多模式镇痛基础上,罗哌卡因联合酮咯酸切口浸润未改善24小时活动痛。
- 两组其他时间点疼痛评分、阿片类药物消耗及首次补救镇痛时间均无显著差异。
- 该研究不支持对已接受鞘内吗啡的剖宫产患者常规加用此切口浸润方案。
核心结论
- 对于接受鞘内吗啡和多模式镇痛方案的剖宫产产妇,罗哌卡因联合酮咯酸切口浸润无额外镇痛获益。
研究设计与样本
- 随机双盲研究,纳入择期剖宫产产妇,比较罗哌卡因0.2%联合酮咯酸与生理盐水安慰剂经弹性泵切口浸润48小时,计划每组35例(共70例),实际按方案完成71例(安慰剂组38例,联合组33例)。
主要发现
- 术后24小时活动痛评分两组中位数差0(95%CI -1~2,P=.94),无显著差异。
- 其他时间点静息痛和活动痛评分均无显著差异。
- 总阿片类药物消耗中位数差-12.5 mg(95%CI -30~5,P=.11),无显著差异。
- 首次补救镇痛时间中位数(四分位距)安慰剂组660(9-1,496)分钟 vs 联合组954(244-1,710)分钟,风险比0.69(95%CI 0.41~1.17,P=.16)。
临床怎么用
- 对于已接受鞘内吗啡和多模式镇痛方案的剖宫产患者,不应常规采用罗哌卡因联合酮咯酸切口浸润以额外改善镇痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of wound infusion with ropivacaine plus ketorolac compared with placebo for post-cesarean delivery analgesia in women who received a multimodal analgesic regimen including intrathecal morphine. METHODS: In a randomized double-blind study, women undergoing scheduled cesarean delivery under spinal or combined spinal epidural anesthesia were randomized to wound infusion with ropivacaine 0.2% plus ketorolac, or saline placebo using an elastometric pump for 48 hours. The primary outcome was pain score with movement at 24 hours after surgery (0-10 scale, 0=no pain and 10=worst possible pain). Secondary outcomes included pain scores at rest at 24 hours, pain scores at rest and with movement at 2 and 48 hours, opioid consumption, and time to first rescue analgesic. A sample size of 35 per group (n=70) was planned. RESULTS: From November 8, 2016, to May 17, 2019, 247 women were screened, and 71 completed the study per protocol: 38 in the placebo group and 33 in the ropivacaine plus ketorolac group. Patient demographics and intraoperative characteristics were comparable between the groups. There was no significant difference between the groups in the primary outcome of pain score with movement at 24 hours (difference in median score 0, 95% CI -1 to 2, P=.94). There were also no significant differences between the placebo and ropivacaine plus ketorolac groups in pain scores at other time points, in total opioid consumption (difference in median consumption -12.5 mg, 95% CI -30 to 5, P=.11), or in time to rescue analgesics (median [interquartile range] 660 [9-1,496] vs 954 [244-1,710] minutes, hazard ratio 0.69, 95% CI 0.41 to 1.17, P=.16). CONCLUSION: There was no benefit of wound infusion with ropivacaine and ketorolac in women who received intrathecal morphine and a multimodal analgesic regimen. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02829944. FUNDING SOURCE: The study was supported in part by Avanos Medical Inc.
引用
- Barney EZ, Pedro CD, Gamez BH, et al. Ropivacaine and Ketorolac Wound Infusion for Post-Cesarean Delivery Analgesia: A Randomized Controlled Trial. Obstet Gynecol. 2020. PMID: 31923061. doi:10.1097/AOG.0000000000003601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。